Umberto Capitanio

List of Publications by Year
in descending order

388 papers	15,400 citations	19657 61 h-index	29157 104 g-index
402 all docs	402 docs citations	402 times ranked	10719 citing authors

#	Article	IF	Citations
1	Epidemiology of Renal Cell Carcinoma. European Urology, 2019, 75, 74-84.	1.9	917
2	Renal cancer. Lancet, The, 2016, 387, 894-906.	13.7	762
3	Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores. European Urology, 2012, 61, 480-487.	1.9	594
4	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. European Urology, 2022, 82, 399-410.	1.9	485
5	Radical versus partial nephrectomy. Cancer, 2009, 115, 1465-1471.	4.1	285
6	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European Urology, 2020, 77, 439-446.	1.9	228
7	Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. European Urology, 2011, 60, 935-943.	1.9	209
8	Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1aâ€“T1b Renal Mass and Normal Preoperative Renal Function. European Urology, 2015, 67, 683-689.	1.9	202
9	Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. Journal of Urology, 2010, 183, 2165-2170.	0.4	186
10	Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2â€“4 pN+ Prostate Cancer: Results of a Matched Analysis. European Urology, 2011, 59, 832-840.	1.9	180
11	More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. European Urology, 2015, 67, 212-219.	1.9	178
12	Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. European Urology, 2009, 56, 1-9.	1.9	161
13	Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. European Urology, 2010, 57, 300-309.	1.9	159
14	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European Urology, 2010, 57, 575-581.	1.9	154
15	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. Journal of Urology, 2010, 183, 68-75.	0.4	146
16	Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. Journal of the National Cancer Institute, 2009, 101, 114-119.	6.3	144
17	The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?. European Urology, 2009, 56, 512-519.	1.9	143
18	Prognostic Value of Lymph Node Dissection in Patients with Muscle-Invasive Transitional Cell Carcinoma of the Upper Urinary Tract. European Urology, 2008, 53, 794-802.	1.9	137

#	Article	IF	Citations
19	When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool. European Urology, 2010, 57, 551-558.	1.9	137
20	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU International, 2010, 105, 1402-1412.	2.5	132
21	A Population Based Assessment of Perioperative Mortality After Cystectomy for Bladder Cancer. Journal of Urology, 2009, 182, 70-77.	0.4	131
22	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 701-710.	1.9	128
23	A Preoperative Prognostic Model for Patients Treated with Nephrectomy for Renal Cell Carcinoma. European Urology, 2009, 55, 287-295.	1.9	121
24	Lymph Node Dissection in Renal Cell Carcinoma. European Urology, 2011, 60, 1212-1220.	1.9	120
25	Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. European Urology, 2012, 61, 1132-1138.	1.9	120
26	A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a populationâ€based study. BJU International, 2009, 103, 1496-1500.	2.5	118
27	Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). European Urology, 2018, 74, 226-232.	1.9	109
28	Can nomograms be superior to other prediction tools?. BJU International, 2009, 103, 492-497.	2.5	108
29	Nerveâ€sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. BJU International, 2013, 111, 717-722.	2.5	108
30	Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2013, 63, 998-1008.	1.9	107
31	The Learning Curve for Robot-assisted Partial Nephrectomy: Impact of Surgical Experience on Perioperative Outcomes. European Urology, 2019, 75, 253-256.	1.9	104
32	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitorâ€"based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. European Urology, 2021, 80, 393-397.	1.9	103
33	Biopsy Core Number Represents One of Foremost Predictors of Clinically Significant Gleason Sum Upgrading in Patients With Low-risk Prostate Cancer. Urology, 2009, 73, 1087-1091.	1.0	102
34	Predicting Erectile Function Recovery after Bilateral Nerve Sparing Radical Prostatectomy: A Proposal of a Novel Preoperative Risk Stratification. Journal of Sexual Medicine, 2010, 7, 2521-2531.	0.6	102
35	Nephron-sparing Surgery Is Equally Effective to Radical Nephrectomy for T1BN0M0 Renal Cell Carcinoma: A Population-based Assessment. Urology, 2010, 75, 271-275.	1.0	98
36	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naÃ¯ve Metastatic Clear-Cell Renal Cell Carcinoma. European Urology, 2021, 79, 339-342.	1.9	98

#	Article	IF	Citations
37	Currently used criteria for active surveillance in men with lowâ€risk prostate cancer. Cancer, 2008, 113, 2068-2072.	4.1	96
38	Benign Prostatic Hyperplasia and Its Aetiologies. European Urology Supplements, 2009, 8, 865-871.	0.1	96
39	Biopsy Schemes with the Fewest Cores for Detecting 95% of the Prostate Cancers Detected by a 24-Core Biopsy. European Urology, 2010, 57, 1-8.	1.9	94
40	The Rate of Secondary Malignancies After Radical Prostatectomy Versus External Beam Radiation Therapy for Localized Prostate Cancer: A Population-Based Study on 17,845 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 76, 342-348.	0.8	93
41	Is Erectile Dysfunction a Reliable Proxy of General Male Health Status? The Case for the International Index of Erectile Functionâ€"Erectile Function Domain. Journal of Sexual Medicine, 2012, 9, 2708-2715.	0.6	92
42	A delay in radical nephroureterectomy can lead to upstaging. BJU International, 2010, 105, 812-817.	2.5	90
43	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 252-258.	1.6	88
44	Partial Versus Radical Nephrectomy in Patients With Adverse Clinical or Pathologic Characteristics. Urology, 2009, 73, 1300-1305.	1.0	87
45	Head-to-Head Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy. Journal of Urology, 2013, 190, 496-501.	0.4	87
46	Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer, 2008, 113, 701-709.	4.1	86
47	Role of Active Surveillance for Localized Small Renal Masses. European Urology Oncology, 2018, 1, 177-187.	5.4	85
48	Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. European Urology, 2018, 74, 661-667.	1.9	84
49	Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres. European Urology, 2020, 78, 11-15.	1.9	84
50	Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. European Urology, 2014, 65, 546-551.	1.9	81
51	Lymphatic spread of nodal metastases in highâ€risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. Prostate, 2012, 72, 186-192.	2.3	79
52	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and metaâ€analysis. BJU International, 2018, 121, 684-698.	2.5	79
53	Partial Cystectomy Does Not Undermine Cancer Control in Appropriately Selected Patients With Urothelial Carcinoma of the Bladder: A Population-based Matched Analysist. Urology, 2009, 74, 858-864.	1.0	77
54	Stageâ€specific effect of nodal metastases on survival in patients with nonâ€metastatic renal cell carcinoma. BJU International, 2009, 103, 33-37.	2.5	75

#	Article	IF	Citations
55	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. European Urology, 2020, 77, 636-643.	1.9	75
56	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. European Urology Oncology, 2019, 2, 141-149.	5.4	73
57	p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU International, 2010, 105, 489-495.	2.5	69
58	Extent of lymph node dissection at nephrectomy affects cancerâ€specific survival and metastatic progression in specific subâ€categories of patients with renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 114, 210-215.	2.5	69
59	Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU International, 2009, 103, 1359-1362.	2.5	67
60	Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma. Urology, 2009, 73, 342-346.	1.0	67
61	The ERUS Curriculum for Robot-assisted Partial Nephrectomy: Structure Definition and Pilot Clinical Validation. European Urology, 2019, 75, 1023-1031.	1.9	64
62	Perioperative Outcomes of Open, Laparoscopic, and Robotic Partial Nephrectomy: A Prospective Multicenter Observational Study (The RECORd 2 Project). European Urology Focus, 2021, 7, 390-396.	3.1	63
63	Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy. Clinical Cancer Research, 2012, 18, 3648-3657.	7.0	62
64	Radical Prostatectomy for Incidental (Stage T1aâ€“T1b) Prostate Cancer: Analysis of Predictors for Residual Disease and Biochemical Recurrence. European Urology, 2008, 54, 118-125.	1.9	61
65	Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. European Urology, 2008, 54, 794-804.	1.9	61
66	Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma. Cancer, 2009, 115, 5680-5687.	4.1	61
67	Impact of clinical factors, including a pointâ€ofâ€care nuclear matrix proteinâ€22 assay and cytology, on bladder cancer detection. BJU International, 2009, 103, 1368-1374.	2.5	61
68	A Population-based Comparison of Cancer-control Rates Between Radical and Partial Nephrectomy for T1A Renal Cell Carcinoma. Urology, 2010, 76, 883-888.	1.0	61
69	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. Journal of Urology, 2020, 203, 496-504.	0.4	61
70	Thirty-Day Mortality After Nephrectomy: Clinical Implications for Informed Consent. European Urology, 2009, 56, 998-1005.	1.9	60
71	Retroperitoneal vs Transperitoneal Robot-assisted Partial Nephrectomy: Comparison in a Multi-institutional Setting. Urology, 2018, 120, 131-137.	1.0	59
72	How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. BJU International, 2011, 107, 1095-1101.	2.5	58

#	Article	IF	Citations
73	Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution. Journal of Urology, 2018, 199, 66-73.	0.4	58
74	Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. Journal of Urology, 2016, 196, 1008-1013.	0.4	57
75	p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. Journal of Urology, 2009, 182, 907-913.	0.4	54
76	Conditional Survival Predictions After Nephrectomy for Renal Cell Carcinoma. Journal of Urology, 2009, 182, 2607-2612.	0.4	52
77	Suture techniques during laparoscopic and robotâ€assisted partial nephrectomy: a systematic review and quantitative synthesis of periâ€operative outcomes. BJU International, 2019, 123, 923-946.	2.5	50
78	Testing the most stringent criteria for selection of candidates for active surveillance in patients with lowâ€risk prostate cancer. BJU International, 2010, 105, 1548-1552.	2.5	49
79	A comparative populationâ€based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. BJU International, 2010, 105, 359-364.	2.5	48
80	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. European Urology, 2021, 80, 575-588.	1.9	48
81	Cancerâ€specific and nonâ€cancerâ€related mortality rates in European patients with T1a and T1b renal cell carcinoma. BJU International, 2009, 103, 894-898.	2.5	47
82	Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors. Urology, 2009, 74, 373-377.	1.0	47
83	Preoperative hypogonadism is not an independent predictor of highâ€risk disease in patients undergoing radical prostatectomy. Cancer, 2011, 117, 3953-3962.	4.1	47
84	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International, 2019, 96, 555-567.	5.2	47
85	External Validation of the Updated Partin Tables in a Cohort of French and Italian Men. International Journal of Radiation Oncology Biology Physics, 2009, 73, 347-352.	0.8	46
86	Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. Journal of Urology, 2018, 199, 1143-1148.	0.4	46
87	Surgical quality, cancer control and functional preservation: introducing a novel trifecta for robot-assisted partial nephrectomy. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 82-90.	3.9	45
88	Mortality at 120 days after prostatic biopsy: A populationâ€based study of 22,175 men. International Journal of Cancer, 2008, 123, 647-652.	5.1	44
89	Baseline renal function, ischaemia time and blood loss predict the rate of renal failure after partial nephrectomy. BJU International, 2009, 103, 1632-1635.	2.5	44
90	End-Stage Renal Disease After Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disorders at Baseline. European Urology, 2016, 70, 558-561.	1.9	44

#	Article	IF	Citations
91	Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. European Urology, 2022, 81, 476-488.	1.9	44
92	Cytoreductive Partial Nephrectomy Does Not Undermine Cancer Control in Metastatic Renal Cell Carcinoma: A Population-Based Study. Urology, 2008, 72, 1090-1095.	1.0	43
93	Systematic Review and Pooled Analysis of the Impact of Renorrhaphy Techniques on Renal Functional Outcome After Partial Nephrectomy. European Urology Oncology, 2019, 2, 572-575.	5.4	43
94	Robot-assisted partial nephrectomy: 7-year outcomes. Minerva Urology and Nephrology, 2021, 73, 540-543.	2.5	43
95	When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during followâ€up. BJU International, 2013, 112, E59-66.	2.5	42
96	Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity scoreâ€matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU International, 2020, 126, 114-123.	2.5	42
97	Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States. Journal of Endourology, 2019, 33, 438-447.	2.1	41
98	Impact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific Survival in Patients with Renal Cell Carcinoma. European Urology, 2011, 60, 358-365.	1.9	39
99	Prediction of delayed graft function after renal transplantation. Canadian Urological Association Journal, 2013, 3, 377.	0.6	39
100	Independent Validation of a Model Predicting the Need for Packed Red Blood Cell Transfusion at Liver Transplantation. Transplantation, 2009, 88, 386-391.	1.0	38
101	What Is the Definition of a Satisfactory Erectile Function After Bilateral Nerve Sparing Radical Prostatectomy?. Journal of Sexual Medicine, 2011, 8, 1210-1217.	0.6	38
102	Is Robot-assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of Morbidity, Renal Function, and Oncologic Outcomes. European Urology Oncology, 2018, 1, 61-68.	5.4	38
103	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2019, 2, 699-707.	5.4	38
104	Clinicians are Most Familiar with Nomograms and Rate their Clinical Usefulness Highest, Look-up Tables are Second Best. European Urology, 2008, 54, 958-959.	1.9	37
105	A populationâ€based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU International, 2009, 103, 899-904.	2.5	37
106	The rationale and the role of lymph node dissection in renal cell carcinoma. World Journal of Urology, 2017, 35, 497-506.	2.2	37
107	Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. European Urology Oncology, 2020, 3, 209-215.	5.4	37
108	Techniques and outcomes of minimally-invasive surgery for nonmetastatic renal cell carcinoma with inferior vena cava thrombosis: a systematic review of the literature. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 339-358.	3.9	37

#	Article	IF	Citations
109	External Validation of the Updated Partin Tables in a Cohort of North American Men. Journal of Urology, 2008, 180, 898-903.	0.4	36
110	Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. Urology, 2018, 122, 152-157.	1.0	36
111	Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA) Tj ETQq1 1 0.784314 rgBT /Overlock 1	2.2	36
112	Circulating estradiol, but not testosterone, is a significant predictor of highâ€grade prostate cancer in patients undergoing radical prostatectomy. Cancer, 2011, 117, 5029-5038.	4.1	35
113	Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. Journal of Urology, 2012, 187, 569-574.	0.4	35
114	Choosing the Best Candidates for Penile Rehabilitation After Bilateral Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 608-617.	0.6	35
115	A Simple and Accurate Model for Prediction of Cancer-Specific Mortality in Patients Treated with Surgery for Primary Penile Squamous Cell Carcinoma. Clinical Cancer Research, 2009, 15, 1013-1018.	7.0	34
116	Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasoundâ€guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU International, 2012, 110, E64-8.	2.5	34
117	Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma. World Journal of Urology, 2021, 39, 1369-1376.	2.2	34
118	Prediction of sexual function after radical prostatectomy. Cancer, 2009, 115, 3150-3159.	4.1	33
119	Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines. European Urology Focus, 2016, 1, 272-281.	3.1	33
120	Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium. European Urology, 2018, 73, 793-799.	1.9	33
121	Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 523-529.	5.4	33
122	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgeryâ€"Results from RECUR Consortium. European Urology Oncology, 2021, 4, 473-482.	5.4	33
123	Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 22-41.	5.4	33
124	The Optimal Rebiopsy Prostatic Scheme Depends on Patient Clinical Characteristics: Results of a Recursive Partitioning Analysis Based on a 24-Core Systematic Scheme. European Urology, 2011, 60, 834-841.	1.9	32
125	Outcomes of robot-assisted partial nephrectomy for completely endophytic renal tumors: A multicenter analysis. European Journal of Surgical Oncology, 2021, 47, 1179-1186.	1.0	32
126	The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU International, 2011, 108, 366-371.	2.5	31

#	Article	IF	Citations
127	Erectile Function Outcome after Bilateral Nerve Sparing Radical Prostatectomy: Which Patients May Be Left Untreated?. Journal of Sexual Medicine, 2012, 9, 903-908.	0.6	31
128	Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World Journal of Urology, 2013, 31, 275-280.	2.2	31
129	Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium. European Urology Focus, 2018, 4, 435-441.	3.1	31
130	Effect of Body Mass Index on Histopathologic Parameters: Results of Large European Contemporary Consecutive Open Radical Prostatectomy Series. Urology, 2009, 73, 615-619.	1.0	30
131	Random biopsy: when, how many and where to take the cores?. World Journal of Urology, 2014, 32, 859-869.	2.2	30
132	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. Journal of Urology, 2016, 195, 1354-1361.	0.4	30
133	The impact of lymph node dissection and positive lymph nodes on cancerâ€specific mortality in contemporary <scp>pT</scp>_{2â€3} nonâ€metastatic renal cell carcinoma treated with radical nephrectomy. BJU International, 2018, 121, 383-392.	2.5	30
134	Systematic Review of the Management of Local Kidney Cancer Relapse. European Urology Oncology, 2018, 1, 512-523.	5.4	30
135	The Role of Ablation and Minimally Invasive Techniques in the Management of Small Renal Masses. European Urology Oncology, 2018, 1, 395-402.	5.4	30
136	Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors. European Urology Focus, 2021, 7, 574-581.	3.1	30
137	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. Journal of the National Cancer Institute, 2021, 113, 48-53.	6.3	30
138	Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma. BJU International, 2008, 102, 1610-1614.	2.5	29
139	Indications for Pelvic Nodal Treatment in Prostate Cancer Should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series. International Journal of Radiation Oncology Biology Physics, 2012, 83, 624-629.	0.8	29
140	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. European Urology, 2022, 81, 134-137.	1.9	29
141	Outcome Predictors of Radical Prostatectomy Followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive Disease. Journal of Urology, 2012, 188, 84-90.	0.4	28
142	Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer, 2020, 18, e723-e729.	1.9	28
143	Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. PLoS ONE, 2017, 12, e0184173.	2.5	28
144	Robotic partial nephrectomy versus radical nephrectomy in elderly patients with large renal masses. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 99-108.	3.9	28

#	Article	IF	Citations
145	Predictive models before and after radical prostatectomy. Prostate, 2010, 70, 1371-1378.	2.3	27
146	â€˜Trifectaâ€™ outcomes of robotâ€assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis. BJU International, 2018, 121, 119-123.	2.5	27
147	Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review. Minerva Urology and Nephrology, 2022, 74, .	2.5	27
148	Race affects access to nephrectomy but not survival in renal cell carcinoma. BJU International, 2009, 103, 889-893.	2.5	26
149	The Extent of Lymphadenectomy does Affect Cancer Specific Survival in Pathologically Confirmed T4 Renal Cell Carcinoma. Urologia, 2012, 79, 109-115.	0.7	26
150	Influence of obesity on tumour volume in patients with prostate cancer. BJU International, 2012, 109, 678-684.	2.5	26
151	Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. Journal of Surgical Oncology, 2016, 114, 764-768.	1.7	26
152	Predicting survival of men with recurrent prostate cancer after radical prostatectomy. European Journal of Cancer, 2016, 54, 27-34.	2.8	26
153	Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 389-407.	3.9	26
154	Assessment of Pathological Prostate Cancer Characteristics in Men with Favorable Biopsy Features on Predominantly Sextant Biopsy. European Urology, 2009, 55, 617-628.	1.9	25
155	A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States. Urology, 2009, 74, 837-841.	1.0	25
156	Prostate Saturation Biopsy following a First Negative Biopsy: State of the Art. Urologia Internationalis, 2012, 89, 126-135.	1.3	25
157	Ageâ€adjusted validation of the most stringent criteria for active surveillance in lowâ€risk prostate cancer patients. Cancer, 2012, 118, 973-980.	4.1	25
158	Radical prostatectomy represents an effective treatment in patients with specimenâ€confined high pathological <scp>G</scp>leason score prostate cancer. BJU International, 2013, 111, 723-730.	2.5	25
159	Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. European Urology, 2020, 78, 321-326.	1.9	25
160	Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 271.e19-271.e27.	1.6	25
161	Peyronie's Disease and Autoimmunityâ€”A Real-Life Clinical Study and Comprehensive Review. Journal of Sexual Medicine, 2015, 12, 1062-1069.	0.6	24
162	Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score â‰¥10) Renal Tumors: A Prospective Multicenter Observational Study (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	24	

#	Article	IF	Citations
163	Comprehensive long-term assessment of outcomes following robot-assisted partial nephrectomy for renal cell carcinoma: the ROMe's achievement and its predicting nomogram. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 482-489.	3.9	24
164	A Nomogram Predicting Prostate Cancer-Specific Mortality after Radical Prostatectomy. Urologia Internationalis, 2010, 84, 132-140.	1.3	23
165	National Comprehensive Cancer Network Practice Guidelines 2011: Need for More Accurate Recommendations for Pelvic Lymph Node Dissection in Prostate Cancer. Journal of Urology, 2012, 188, 423-428.	0.4	23
166	Nomogram for predicting the likelihood of postoperative surgical complications in patients treated with partial nephrectomy: a prospective multicentre observational study (the <scp>RECOR</scp>d 2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.8	23
167	Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project). World Journal of Urology, 2020, 38, 151-158.	2.2	23
168	Percutaneous Microwave Ablation Versus Cryoablation in the Treatment of T1a Renal Tumors. CardioVascular and Interventional Radiology, 2020, 43, 76-83.	2.0	23
169	The Impact of Surgical Strategy in Robot-assisted Partial Nephrectomy: Is It Beneficial to Treat Anterior Tumours with Transperitoneal Access and Posterior Tumours with Retroperitoneal Access?. European Urology Oncology, 2021, 4, 112-116.	5.4	23
170	Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy. International Journal of Urology, 2013, 20, 572-579.	1.0	22
171	Virtual Reality Validation of the ERUS Simulation-based Training Programmes: Results from a High-volume Training Centre for Robot-assisted Surgery. European Urology, 2019, 75, 885-887.	1.9	22
172	Development and External Validation of a Highly Accurate Nomogram for the Prediction of Perioperative Mortality After Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Journal of Urology, 2009, 182, 626-632.	0.4	21
173	Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerveâ€sparing radical prostatectomy. International Journal of Urology, 2013, 20, 413-419.	1.0	21
174	Secondary Provoked Vestibulodynia in Sexually Active Women with Uncomplicated Recurrent Urinary Tract Infections. Journal of Sexual Medicine, 2013, 10, 2265-2273.	0.6	21
175	Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1037-1045.	0.8	21
176	Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (The RECORD 2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.8	21
177	Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. BJU International, 2011, 108, 1769-1775.	2.5	20
178	Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Current Medical Research and Opinion, 2014, 30, 719-732.	1.9	20
179	European temporal trends in the use of lymph node dissection in patients with renal cancer. European Journal of Surgical Oncology, 2017, 43, 2184-2192.	1.0	20
180	mTORC1ÂUpregulation Leads to Accumulation of the Oncometabolite Fumarate in a Mouse Model of Renal Cell Carcinoma. Cell Reports, 2018, 24, 1093-1104.e6.	6.4	20

#	Article	IF	Citations
181	Trifecta Outcomes of Partial Nephrectomy in Patients Over 75 Years Old: Analysis of the REnal SURGery in Elderly (RESURGE) Group. European Urology Focus, 2020, 6, 982-990.	3.1	20
182	Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. Urology, 2020, 138, 60-68.	1.0	20
183	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. European Urology Oncology, 2021, 4, 829-833.	5.4	20
184	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 10.e1-10.e6.	1.6	20
185	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nature Reviews Urology, 2022, 19, 391-418.	3.8	20
186	External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU International, 2009, 104, 1661-1667.	2.5	19
187	When should we expect no residual tumor (pT0) once we submit incidental T1aâ€b prostate cancers to radical prostatectomy?. International Journal of Urology, 2011, 18, 148-153.	1.0	19
188	Staging lymphadenectomy in renal cell carcinoma must be extended: a sensitivity curve analysis. BJU International, 2013, 111, 412-418.	2.5	19
189	The Number of Cores Taken in Patients Diagnosed with a Single Microfocus at Initial Biopsy is a Major Predictor of Insignificant Prostate Cancer. Journal of Urology, 2013, 189, 854-859.	0.4	19
190	Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion. World Journal of Urology, 2016, 34, 1139-1145.	2.2	19
191	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Cancer Epidemiology, 2018, 56, 118-125.	1.9	19
192	Preoperative frailty predicts adverse shortâ€term postoperative outcomes in patients treated with radical nephroureterectomy. Journal of Surgical Oncology, 2020, 121, 688-696.	1.7	19
193	The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. International Journal of Urology, 2009, 16, 526-529.	1.0	18
194	Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). BJU International, 2009, 104, 795-799.	2.5	18
195	Sex Hormone-binding Globulin: A Novel Marker for Nodal Metastases Prediction in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection. Urology, 2009, 73, 850-855.	1.0	18
196	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. European Journal of Surgical Oncology, 2019, 45, 1983-1992.	1.0	18
197	Assessment of volume preservation performed before or after partial nephrectomy accurately predicts postoperative renal function: Results from a prospective multicenter study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 33-39.	1.6	18
198	Warm ischemia time length during on-clamp partial nephrectomy: does it really matter?. Minerva Urology and Nephrology, 2022, 74, .	2.5	18

#	Article	IF	Citations
199	Long-term recovery of normal sexual function in testicular cancer survivors. Asian Journal of Andrology, 2016, 18, 85.	1.6	18
200	Estimated Glomerular Filtration Rate Decline at 1 Year After Minimally Invasive Partial Nephrectomy: A Multimodel Comparison of Predictors. European Urology Open Science, 2022, 38, 52-59.	0.4	18
201	High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer. BJU International, 2008, 102, 463-467.	2.5	17
202	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerveâ€Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 2187-2194.	0.6	17
203	Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?. Journal of Endourology, 2016, 30, 400-405.	2.1	17
204	Current Status of Focal Cryoablation for Small Renal Masses. Urology, 2016, 90, 9-15.	1.0	17
205	Conversion of Robot-assisted Partial Nephrectomy to Radical Nephrectomy: A Prospective Multi-institutional Study. Urology, 2018, 113, 85-90.	1.0	17
206	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. European Urology, 2021, 80, 149-159.	1.9	17
207	Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Canadian Urological Association Journal, 2009, 3, 13-21.	0.6	17
208	Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs. World Journal of Urology, 2015, 33, 873-880.	2.2	16
209	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. European Urology, 2016, 70, 429-435.	1.9	16
210	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, 176-183.	1.9	16
211	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. Clinical Genitourinary Cancer, 2018, 16, e903-e908.	1.9	16
212	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. World Journal of Urology, 2018, 36, 51-57.	2.2	16
213	Head to Head Impact of Margin, Ischemia, Complications, Score Versus a Novel Trifecta Score on Oncologic and Functional Outcomes After Robotic-assisted Partial Nephrectomy: Results of a Multicenter Series. European Urology Focus, 2021, 7, 1391-1399.	3.1	16
214	Chronic Kidney Disease After Partial Nephrectomy in Patients With Preoperative Inconspicuous Renal Function â€“ Curiosity or Relevant Issue?. Clinical Genitourinary Cancer, 2020, 18, e754-e761.	1.9	16
215	Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORd 2 project). European Journal of Surgical Oncology, 2020, 46, 1353-1359.	1.0	16
216	Multi-Institutional External Validation of Seminal Vesicle Invasion Nomograms: Head-to-Head Comparison of Gallina Nomogram Versus 2007 Partin Tables. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1461-1467.	0.8	15

#	Article	IF	Citations
217	Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?. Urology, 2009, 74, 842-845.	1.0	15
218	Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer. Journal of Urology, 2009, 182, 459-465.	0.4	15
219	Renal Tumor Biopsy: More Dogma Belied. European Urology, 2015, 68, 1014-1015.	1.9	15
220	Populationâ€based assessment of cancerâ€specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. BJU International, 2016, 118, 541-546.	2.5	15
221	Upstaging to pT3a disease in patients undergoing robotic partial nephrectomy for cT1 kidney cancer: Outcomes and predictors from a multi-institutional dataset. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 286-292.	1.6	15
222	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. World Journal of Urology, 2021, 39, 461-472.	2.2	15
223	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. European Urology Focus, 2022, 8, 182-190.	3.1	15
224	Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. Prostate, 2012, 72, 499-506.	2.3	14
225	Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. World Journal of Urology, 2017, 35, 1031-1036.	2.2	14
226	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urologic Oncology: Seminars and Original Investigations, 2018, 36, 79.e11-79.e17.	1.6	14
227	Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. Scientific Reports, 2019, 9, 13218.	3.3	14
228	Should partial nephrectomy be considered â€œelectiveâ€• in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy. World Journal of Urology, 2019, 37, 2429-2437.	2.2	14
229	Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology. Advances in Therapy, 2019, 36, 1-18.	2.9	14
230	Predicting intraâ€operative and postoperative consequential events using machineâ€learning techniques in patients undergoing robotâ€assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study. BJU International, 2020, 126, 350-358.	2.5	14
231	Parenchymal biopsy in the management of patients with renal cancer. World Journal of Urology, 2021, 39, 2961-2968.	2.2	14
232	Risk factors for progression of chronic kidney disease after robotic partial nephrectomy in elderly patients: results from a multi-institutional collaborative series. Minerva Urology and Nephrology, 2022, 74, .	2.5	14
233	Assessment of Biochemical Recurrence Rate in Patients With Pathologically Confirmed Insignificant Prostate Cancer. Urology, 2008, 72, 1208-1211.	1.0	13
234	The extent of tumour fat invasion affects survival in patients with renal cell carcinoma and venous tumour thrombosis. BJU International, 2011, 108, no-no.	2.5	13

#	Article	IF	Citations
235	Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1497-1503.	1.6	13
236	Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy. Annals of Surgical Oncology, 2019, 26, 1942-1949.	1.5	13
237	Toward Individualized Approaches to Partial Nephrectomy: Assessing the Correlation Between Ischemia Time and Patient Health Status (RECORD2 Project). European Urology Oncology, 2021, 4, 645-650.	5.4	13
238	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 537-544.	1.6	13
239	Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. BJU International, 2021, 128, 722-727.	2.5	13
240	A nomogram predicting metastatic progression after radical prostatectomy. International Journal of Urology, 2008, 15, 889-894.	1.0	12
241	Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort. Urology, 2009, 73, 1323-1327.	1.0	12
242	Optimizing postoperative sexual function after radical prostatectomy. Therapeutic Advances in Urology, 2012, 4, 347-365.	2.0	12
243	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies. Prostate, 2012, 72, 925-930.	2.3	12
244	Repeat Prostate Biopsy: Rationale, Indications, and Strategies. European Urology Focus, 2015, 1, 127-136.	3.1	12
245	Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?. European Urology Focus, 2018, 4, 972-977.	3.1	12
246	The Effect of Anatomical Location of Lymph Node Metastases on Cancer Specific Survival in Patients with Clear Cell Renal Cell Carcinoma. Frontiers in Surgery, 2018, 5, 26.	1.4	12
247	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. International Urology and Nephrology, 2019, 51, 2181-2188.	1.4	12
248	Do We Truly Care About the Functional Outcomes for Renal Cancer Patients? Multidisciplinarity Is Still Far Away. European Urology, 2019, 75, 349-350.	1.9	12
249	The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery. World Journal of Urology, 2021, 39, 2553-2558.	2.2	12
250	Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes. European Urology, 2021, 80, 730-737.	1.9	12
251	A Nomogram for the Prediction of Intermediate Significant Renal Function Loss After Robot-assisted Partial Nephrectomy for Localized Renal Tumors: A Prospective Multicenter Observational Study (RECORd2 Project). European Urology Focus, 2022, 8, 980-987.	3.1	12
252	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. European Journal of Surgical Oncology, 2022, 48, 687-693.	1.0	12

#	Article	IF	Citations
253	Sex hormoneâ€binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. BJU International, 2011, 107, 1243-1249.	2.5	11
254	The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: Conditional survival analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 43.e9-43.e16.	1.6	11
255	Lymph node dissection for renal cell carcinoma. Current Opinion in Urology, 2016, 26, 424-431.	1.8	11
256	Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer. Urology, 2017, 102, 130-137.	1.0	11
257	Lymph node dissection should not be dismissed in case of localized renal cell carcinoma in the presence of larger diseases. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 662.e9-662.e15.	1.6	11
258	When to perform preoperative chest computed tomography for renal cancer staging. BJU International, 2017, 120, 490-496.	2.5	11
259	Risk Based Surveillance after Surgical Treatment of Renal Cell Carcinoma. Journal of Urology, 2018, 200, 61-67.	0.4	11
260	Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. Kidney and Blood Pressure Research, 2020, 45, 166-179.	2.0	11
261	Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. World Journal of Urology, 2021, 39, 1195-1201.	2.2	11
262	Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. European Journal of Surgical Oncology, 2021, 47, 1187-1190.	1.0	11
263	Retroperitoneal versus transepritoneal robot-assisted partial nephrectomy for postero-lateral renal masses: an international multicenter analysis. World Journal of Urology, 2021, 39, 4175-4182.	2.2	11
264	Renal cancer: overdiagnosis and overtreatment. World Journal of Urology, 2021, 39, 2821-2823.	2.2	11
265	Body Mass Index and its Association with Genitourinary Disorders in Men Undergoing Prostate Cancer Screening. Journal of Sexual Medicine, 2008, 5, 2141-2151.	0.6	10
266	Contemporary management of patients with T1a and T1b prostate cancer. Current Opinion in Urology, 2011, 21, 252-256.	1.8	10
267	The critical role of lymph node dissection in selecting high-risk nonmetastatic renal cancer candidates for adjuvant therapy after nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 293.e25-293.e30.	1.6	10
268	Technical and Functional Validation of a Teleoperated Multirobots Platform for Minimally Invasive Surgery. IEEE Transactions on Medical Robotics and Bionics, 2020, 2, 148-156.	3.2	10
269	The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 554-560.	6.4	10
270	How to Select the Optimal Candidates for Renal Mass Biopsy. European Urology Oncology, 2021, 4, 506-509.	5.4	10

#	Article	IF	Citations
271	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e15-235.e21.	1.6	10
272	Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. European Urology Oncology, 2022, 5, 125-133.	5.4	10
273	External validation of the Palaciosâ€™ equation: a simple and accurate tool to estimate the new baseline renal function after renal cancer surgery. World Journal of Urology, 2022, 40, 467-473.	2.2	10
274	Reply to Michael Staehler's Letter to the Editor re: Pierre I Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. Eur Urol 2008;53:845-848. European Urology, 2008, 54, 951-953.	1.9	9
275	Adjuvant radiotherapy after radical prostatectomy shows no ability to improve rates of overall and cancerâ€specific survival in a matched caseâ€control study. BJU International, 2009, 103, 597-602.	2.5	9
276	The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management. European Urology, 2011, 60, 75-77.	1.9	9
277	Outcomes of Partial and Radical Nephrectomy in Octogenarians â€“ A Multicenter International Study (Resurge). Urology, 2019, 129, 139-145.	1.0	9
278	Omission of Cortical Renorrhaphy During Robotic Partial Nephrectomy: A Vattikuti Collective Quality Initiative Database Analysis. Urology, 2020, 146, 125-132.	1.0	9
279	Effect of Obesity and Overweight Status on Complications and Survival After Minimally Invasive Kidney Surgery in Patients with Clinical T₂₋₄ Renal Masses. Journal of Endourology, 2020, 34, 289-297.	2.1	9
280	Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium. World Journal of Urology, 2021, 39, 2969-2975.	2.2	9
281	Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis. Minerva Urology and Nephrology, 2020, , .	2.5	9
282	External Validation of the ASSURE Model for Predicting Oncological Outcomes After Resection of High-risk Renal Cell Carcinoma (RESCUE Study: UroCCR 88). European Urology Open Science, 2021, 33, 89-93.	0.4	9
283	Prediction of significant renal function decline after open, laparoscopic, and robotic partial nephrectomy: External validation of the Martiniâ€™s nomogram on the RECORD2 project cohort. International Journal of Urology, 2022, 29, 525-532.	1.0	9
284	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urology and Nephrology, 2022, 74, 186-193.	2.5	9
285	Effect of body mass index on prostateâ€specific antigen and percentage free prostateâ€specific antigen: Results from a prostate cancer screening cohort of 1490 men. International Journal of Urology, 2009, 16, 91-95.	1.0	8
286	Circulating sex steroids and prostate cancer: introducing the time-dependency theory. World Journal of Urology, 2013, 31, 267-273.	2.2	8
287	The Number of Cores at First Biopsy MayÂSuggest the Need for a Confirmatory Biopsy in Patients Eligible for Active Surveillanceâ€”Implication for Clinical Decision Making in the Real-life Setting. Urology, 2014, 84, 634-641.	1.0	8
288	Comparison of functional outcomes of robotic and open partial nephrectomy in patients with pre-existing chronic kidney disease: a multicenter study. World Journal of Urology, 2018, 36, 1255-1262.	2.2	8

#	Article	IF	Citations
289	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Review of Anticancer Therapy, 2019, 19, 739-755.	2.4	8
290	Is partial nephrectomy safe and effective in the setting of frail comorbid patients affected by renal cell carcinoma? Insights from the RECORD 2 multicentre prospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 78.e17-78.e26.	1.6	8
291	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. Surgical Oncology, 2021, 38, 101588.	1.6	8
292	Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. European Urology Focus, 2018, 4, 834-841.	3.1	7
293	Acute kidney injury after partial nephrectomy: transient or permanent kidney damage?â€"Impact on long-term renal function. Annals of Translational Medicine, 2019, 7, S317-S317.	1.7	7
294	The side and the location of the primary tumor does not affect the probability of lymph node invasion in patients with renal cell carcinoma. World Journal of Urology, 2019, 37, 1623-1629.	2.2	7
295	Robotic-assisted Partial Nephrectomy for â€œVery Smallâ€•(<2 cm) Renal Mass: Results of a Multicenter Contemporary Cohort. European Urology Focus, 2021, 7, 1115-1120.	3.1	7
296	How to improve outcome in nephron-sparing surgery: the impact of new techniques. Current Opinion in Urology, 2021, 31, 255-261.	1.8	7
297	Predicting Complications After Robotic Partial Nephrectomy: Back to Simplicity. European Urology Focus, 2022, 8, 777-783.	3.1	7
298	Outcomes in robotâ€assisted partial nephrectomy for imperative vs elective indications. BJU International, 2021, 128, 30-35.	2.5	7
299	Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into Opportunities. European Urology, 2022, 81, 574-575.	1.9	7
300	Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. World Journal of Urology, 2012, 30, 533-539.	2.2	6
301	Time of onset of vardenafil orodispersible tablet in a real-life setting â€“ looking beyond randomized clinical trials. Expert Review of Clinical Pharmacology, 2017, 10, 1-6.	3.1	6
302	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e9-239.e15.	1.6	6
303	Pathological High-risk Renal Cell Carcinoma: Trends in Clinical Characteristics Over 25 Years. Anticancer Research, 2018, 38, 4123-4130.	1.1	6
304	Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?. European Urology, 2019, 76, 441-442.	1.9	6
305	Renal function outcomes in patients with muscleâ€invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PUREâ€01 study. International Journal of Cancer, 2021, 149, 186-190.	5.1	6
306	Incidental Prostate Cancer (cT1aâ€“cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. European Urology Oncology, 2021, , .	5.4	6

#	Article	IF	Citations
307	Is Hypertension Associated with Worse Renal Functional Outcomes after Minimally Invasive Partial Nephrectomy? Results from a Multi-Institutional Cohort. Journal of Clinical Medicine, 2022, 11, 1243.	2.4	6
308	Editorial Comment to Risk factors for pelvic lymphoceles postâ€radical prostatectomy. International Journal of Urology, 2011, 18, 644-645.	1.0	5
309	Repeated biopsy in the detection of prostate cancer: When and how many cores. Archivio Italiano Di Urologia Andrologia, 2014, 86, 311.	0.8	5
310	Partial Nephrectomy for Large or Complex Masses: Option or Obsolete?. European Urology, 2017, 72, 76-77.	1.9	5
311	When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging. Urology, 2017, 110, 114-120.	1.0	5
312	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World Journal of Urology, 2019, 37, 1631-1637.	2.2	5
313	Renal surgery for the older population: time for a paradigm shift? Data from the RESURGE project. Aging Clinical and Experimental Research, 2020, 32, 173-178.	2.9	5
314	Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 521-525.	1.6	5
315	Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. World Journal of Urology, 2021, 39, 3377-3383.	2.2	5
316	Should patients with lowâ€risk renal cell carcinoma be followed differently after nephronâ€sparing surgery vs radical nephrectomy?. BJU International, 2021, 128, 386-394.	2.5	5
317	High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?. Current Problems in Cancer, 2021, 45, 100759.	2.0	5
318	Unexpected Outcomes of Renal Function after Radical Nephrectomy: Histology Relevance along with Clinical Aspects. Journal of Clinical Medicine, 2021, 10, 3322.	2.4	5
319	Simplified PADUA renal (SPARE) nephrometry score validation and long-term outcomes after robot-assisted partial nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 65.e1-65.e9.	1.6	5
320	GSU: misclassification or biological progression?. Nature Reviews Urology, 2011, 8, 65-66.	3.8	4
321	Leydig cell tumor of the spermatic cord in an adolescent affected by congenital adrenal hyperplasia. International Journal of Urology, 2012, 19, 954-956.	1.0	4
322	Onset of hydronephrosis and lower urinary tract symptoms in a previously healthy young man: Phyllodes tumour of the prostate as a potential diagnosis.. Canadian Urological Association Journal, 2014, 8, 561.	0.6	4
323	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. BJU International, 2015, 116, 366-372.	2.5	4
324	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 57	1.0	4

#	Article	IF	Citations
325	Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma. World Journal of Urology, 2019, 37, 701-708.	2.2	4
326	Postoperative complications increase the risk of longâ€term chronic kidney disease after nephronâ€sparing surgery in patients with renal cancer and normal preoperative renal function. BJU International, 2019, 124, 457-461.	2.5	4
327	Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. Urologia Internationalis, 2019, 102, 51-59.	1.3	4
328	The Association of Uromodulin Genotype with Renal Cancer Aggressiveness. European Urology Focus, 2019, 5, 262-265.	3.1	4
329	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. European Urology Focus, 2021, 7, 1092-1099.	3.1	4
330	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. International Journal of Clinical Oncology, 2021, 26, 962-970.	2.2	4
331	Outcomes of minimally invasive partial nephrectomy among very elderly patients: report from the RESURGE collaborative international database. Central European Journal of Urology, 2020, 73, 273-279.	0.3	4
332	Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021;385:683â€“94. European Urology, 2021, 81, e28-e28.	1.9	4
333	Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis. Minerva Urology and Nephrology, 2022, 73, .	2.5	4
334	Thirty-Day Mortality After Transurethral Resection of the Prostate in Patients Treated with Androgen Deprivation Therapy. Journal of Endourology, 2009, 23, 1347-1352.	2.1	3
335	Suspected Clinical T3 Prostate Cancer Is Associated with a High Rate of Negative Extended Biopsies: Clinical Implications. European Urology, 2009, 55, 253-254.	1.9	3
336	Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active Surveillance in Metastatic Renal-cell Carcinoma: A Prospective, Phase 2 Trial. Lancet Oncol Lancet 2016;17:1317â€“24. European Urology, 2017, 71, e139-e140.	1.9	3
337	Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication. Cancers, 2020, 12, 3345.	3.7	3
338	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. Minerva Urology and Nephrology, 2020, , .	2.5	3
339	Outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter study. Central European Journal of Urology, 2020, 73, 33-38.	0.3	3
340	Von Hippelâ€“Lindau disease-associated renal cell carcinoma: a call to action. Current Opinion in Urology, 2022, 32, 31-39.	1.8	3
341	Cytoreductive Nephrectomy in 2021: Obsolete but Necessary. European Urology Open Science, 2022, 36, 41-43.	0.4	3
342	The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy. European Journal of Surgical Oncology, 2022, 48, 1840-1847.	1.0	3

#	Article	IF	Citations
343	Radiomic and gEnomic approaches for the enhanced DIagnosis of clear cell REnal Cancer (REDIRECt): a translational pilot methodological study. Translational Andrology and Urology, 2022, 11, 149-158.	1.4	3
344	Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol. 2022;81:576â€“85.. European Urology, 2022, 81, e149.	1.9	3
345	Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 384.e15-384.e21.	1.6	3
346	Re: Surgical Outcomes in the Management of Isolated Nodal Recurrences: A Multicenter, International Retrospective Cohort. European Urology, 2015, 67, 974-975.	1.9	2
347	MP41-11 RESECTION TECHNIQUES FOR NEPHRON SPARING SURGERY (NSS) VARY: INSIGHTS FROM A PROSPECTIVELY COLLECTED MULTI-INSTITUTIONAL COHORT HARNESSING THE SURFACEâ€“INTERMEDIATEâ€“BASE (S.I.B.) MARGIN SCORE (SIB INTERNATIONAL CONSORTIUM). Journal of Urology, 2016, 195, .	0.4	2
348	MP59-05 CRITICAL ANALYSIS AND ASSESSMENT OF CLINICAL UTILITY OF NEPHROMETRY SCORES FOR THE PREDICTION OF COMPLICATIONS AFTER NEPHRON SPARING SURGERY. Journal of Urology, 2017, 197, .	0.4	2
349	Organ Preservation Is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinomaâ€”Results of a Comprehensive Multicenter Study. Urology, 2017, 109, 107-114.	1.0	2
350	You Can Trust a Crystal Ball About as Far as You Can Throw It. European Urology, 2018, 73, 781-782.	1.9	2
351	Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy. BJU International, 2019, 124, 6-7.	2.5	2
352	The significance of a high preoperative PSA level for the detection of incidental prostate cancer in LUTS patients with large prostates. World Journal of Urology, 2022, 40, 1063-1064.	2.2	2
353	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. World Journal of Urology, 2021, 39, 3823-3831.	2.2	2
354	MP21-02â€ƒTHE IMPACT OF INTRAOPERATIVE BLEEDING ON THE RISK OF CHRONIC KIDNEY DISEASE AFTER NEPHRON-SPARING SURGERY. Journal of Urology, 2020, 203, .	0.4	2
355	Acute Kidney Injury at Hospital Admission for SARS-CoV-2 Infection as a Marker of Poor Prognosis: Clinical Implications for Triage Risk Stratification. Kidney and Blood Pressure Research, 2022, 47, 147-150.	2.0	2
356	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. Minerva Urology and Nephrology, 2022, 73, .	2.5	2
357	Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 384.e9-384.e14.	1.6	2
358	Editorial Comment on: Prostate Growth and Prevalence of Prostate Diseases in Early Onset Spinal Cord Injuries. European Urology, 2009, 56, 149-150.	1.9	1
359	Spatial distribution of positive cores improves the selection of patients with lowâ€risk prostate cancer as candidates for active surveillance. BJU International, 2013, 112, E234-42.	2.5	1
360	Against the Role of Inflammatory Markers in Renal Cell Carcinoma Prognosis: The Missing Link Between Evidence of Association and Clinical Applicability. European Urology Focus, 2016, 2, 343-344.	3.1	1

#	Article	IF	Citations
361	Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery. European Urology Oncology, 2018, 1, 538-539.	5.4	1
362	Reply from Authors re: Jens. J. Rassweiler, Marcel Fiedler-Hruza. The Learning Curve for Robot-assisted Partial Nephrectomy: There is Much Beyond a Trifecta. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.022. European Urology, 2019, 75, 259-260.	1.9	1
363	Reply to Vincenzo Ficarra, Giuseppe Mucciardi, and Gianluca Giannarini's Letter to the Editor re: Riccardo Campi, Daniele Amparore, Umberto Capitanio, et al. Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres. Eur Urol2020;78:11â€“15. European Urology, 2020, 78, e169-e170.	1.9	1
364	Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1â€“4Âcm renal cell carcinomas. Cancer Causes and Control, 2021, 32, 119-126.	1.8	1
365	Robot-Assisted Partial Nephrectomy for Multiple Renal Tumors: A Vattikuti Collective Quality Initiative Database Analysis. Videourology (New Rochelle, N Y), 2018, 32, .	0.1	1
366	Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?. Annals of Translational Medicine, 2016, 4, 291-291.	1.7	1
367	Reply by Authors. Journal of Urology, 2020, 203, 503-504.	0.4	1
368	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 45	1.0	1
369	SIGIRR Downregulation and Interleukin-1 Signaling Intrinsic to Renal Cell Carcinoma. Frontiers in Oncology, 0, 12, .	2.8	1
370	Editorial <scp>C</scp>omment to <scp>N</scp>odal involvement at nephrectomy is associated with worse survival: A stageâ€forâ€stage and gradeâ€forâ€grade analysis. International Journal of Urology, 2013, 20, 380-381.	1.0	0
371	Reply from Authors re: Steven C. Campbell, Wen Dong, Joe Zabell, Diego Aguilar Palacios. End-stage Renal Disease After Renal Surgery: Partial Nephrectomy Is Protective, but to What Degree and Consequence? Eur Urol 2016;70:562â€“3. European Urology, 2016, 70, 564-565.	1.9	0
372	Reply to Kazutaka Saito's Words of Wisdom re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1aâ€“T1b Renal Mass and Normal Preoperative Renal Function. Eur Urol. 2016;69:538. European Urology, 2016, 70, e135.	1.9	0
373	Oncologic Surveillance for Renal Cell Carcinoma: What Is Still Needed?. European Urology, 2016, 70, 899-900.	1.9	0
374	SP236THE RADICAL NEPHRECTOMY PARADOX: THE UNEXPECTED AKI'S RISK. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
375	SP267RENAL HISTOLOGY VERSUS ESTIMATED GLOMERULAR FILTRATION RATE: BEYOND THE LOOKING GLASS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
376	Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Antonelli A, Minervini A, Sandri M, et al. Eur Urol 2018;74:661â€“7 and 2019;75:198. European Urology, 2019, 76, e17-e18.	1.9	0
377	Re: Ricardo G. Alvim, FranÃ§ois Audenet, Emily A. Vertosick, Daniel D. Sjoberg, Karim A. Touijer. Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL, and PADUA Systems. Eur Urol Oncol 2018;1:428â€“34. European Urology Oncology, 2019, 2, 228-229.	5.4	0
378	Editorial Comment from Dr Martini etÂal. to Independent external validation of a nomogram to define risk categories for a significant decline in estimated glomerular filtration rate after roboticâ€assisted partial nephrectomy. International Journal of Urology, 2021, 28, 80-81.	1.0	0

#	Article	IF	Citations
379	Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002. European Urology Focus, 2021, 7, 406.	3.1	0
380	Editorial Comment. Journal of Urology, 2021, 205, 1292-1292.	0.4	0
381	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press. European Urology Oncology, 2021, 5, 261-261.	5.4	0
382	B2B: Kidney Cancer Summary. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, S19-S28.	0.4	0
383	Factors predicting renal function after partial nephrectomy: A multi-institutional analysis of data from the SIB working group.. Journal of Clinical Oncology, 2016, 34, e16063-e16063.	1.6	0
384	Editorial Comment. Journal of Urology, 2019, 201, 1096-1096.	0.4	0
385	MO165: The Controversial Role of Proteinuria and Urinary Output After Radical Nephrectomy in the Development Of Acute Kidney Injury: Double Agents. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
386	MO155: The Importance of Measured GFR in Clinical Practice: An Old Knowledge for Nephrologists, a New Challenge for Oncologists and Surgeons. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
387	MO189: The Clinical Relevance of Measured GFR in Patients with Solitary Kidney after Radical Nephrectomy: The Estimation is not Enough. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
388	Reply to Sebastiano Buti and Giulia Claire Giudice's Letter to the Editor comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: Is AUC close enough to clinical practice? Urol Oncol. 2022 Apr 14:S1078-1439(22)00066-7. doi: 10.1016/j.urolonc.2022.02.015.. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0